|
 But COVAX, which is co-led by the GAVI vaccine alliance, the World
Health Organization (WHO) and others, said there were many
uncertainties affecting the procurement and supply of COVID-19
vaccines, and terms of the deals were "subject to change".
The 1.8 billion doses would be supplied via an advance market
commitment (AMC) to 92 eligible countries and would correspond to
approximately 27% coverage of populations in those countries, GAVI
said in an updated forecast for COVAX.
"Our forecasting indicates that we should fulfil the requests for
vaccine placed by self-financing participants in the second half of
2021," it said.
Some supply deals were still in negotiation, it said, and some of
the candidate vaccines have yet to be approved for use by medicines
regulators or the WHO. In many cases, manufacturing of the vaccines
had yet to reach full scale, it said.
[to top of second column] |
 "There are many uncertainties
affecting the supply of COVID-19 vaccines in
2021, not least around manufacturing capacity,
regulation, funding availability, final contract
terms and the readiness of countries themselves
to begin their national COVID-19 vaccination
programmes," the COVAX forecast statement said.
"Manufacturing productivity will be influenced
by multiple factors, which will in turn
influence volume and timing of supply."
(Reporting by Kate Kelland; Editing by Alison
Williams, Robert Birsel)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
